Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Inhibitory Killer-cell Immunoglobulin-like Receptor (iKIR)
- Target
- iKIR
- Molecular classification
- Receptor, Immunoglobulin-like Receptor, Type I transmembrane protein
01
Overview
Inhibitory Killer-cell Immunoglobulin-like Receptors (iKIRs) are a family of receptors expressed on NK cells and some T cells that recognize MHC class I molecules. iKIRs deliver inhibitory signals, preventing NK cells from killing healthy cells. The interaction between iKIRs and MHC class I molecules is critical for maintaining self-tolerance and regulating immune responses. Polymorphisms in KIR genes and their ligands contribute to individual differences in immune responses and disease susceptibility.
- Other names
- Inhibitory KIRKIR2DL1KIR2DL2KIR2DL3KIR2DL4KIR3DL1Killer-cell Immunoglobulin-like Receptor (Inhibitory)Inhibitory Natural Killer Cell Receptor
02
Mechanism of action
Phosphorylation of ITIMs recruits phosphatases (SHP-1/SHP-2) that dephosphorylate signaling proteins, inhibiting NK cell activation.
03
Biological functions
Immune responseNatural killer cell regulationSelf-toleranceInhibition of cytotoxicity
04
Disease associations
Autoimmune diseasesCancerViral infectionsTransplant rejectionPregnancy complications
05
Safety considerations
Autoimmunity (due to disruption of self-tolerance)Increased susceptibility to infections (due to impaired NK cell function)Cytokine release syndromeOn-target, off-tumor effects
06
Interacting drugs
Monoclonal antibodies (targeting KIRs or their ligands)
2 more in the full profile.
07
Biomarkers
KIR gene copy numberKIR allele frequencyKIR ligand (HLA) expression levelsPhosphorylation status of ITIMsNK cell activity
Beyond the preview
Go deeper on Inhibitory Killer-cell Immunoglobulin-like Receptor (iKIR).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Inhibitory Killer-cell Immunoglobulin-like Receptor (iKIR).